BRIGHT Trial
Single Arm Phase II Study of Bladder Preservation With Immunoradiotherapy After a Clinically Meaningful Response to Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer
View on ClinicalTrials.gov · NCT07061964Research & Innovation
Dr. Kluwe practices within an academic, NCI-designated cancer center — placing his patients close to ongoing advances in cancer research and treatment.
Mays Cancer Center
The Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, is the only National Cancer Institute‑designated cancer center in Central and South Texas, and one of just four in the entire state.
One of only four National Cancer Institute‑designated cancer centers in Texas.
More than 100 faculty members across 10+ academic departments and 3 schools.
Home to one of the largest oncology Phase I clinical drug development programs in the world.
Clinical Trials
As part of an academic, NCI-designated cancer center, Dr. Kluwe’s practice is closely connected to ongoing clinical research in radiation oncology and cancer care more broadly. Eligibility for any specific clinical trial depends on your individual diagnosis and health history.
If you are interested in learning whether a clinical trial may be appropriate for your diagnosis, please bring this up during your consultation with Dr. Kluwe or contact our office directly.
Participating Investigator
Dr. Kluwe is a participating investigator on the clinical trials listed below. Status and eligibility can change over time — visit each trial’s official listing on ClinicalTrials.gov, the U.S. National Institutes of Health trial registry, for the most current details, or ask our office directly.
Single Arm Phase II Study of Bladder Preservation With Immunoradiotherapy After a Clinically Meaningful Response to Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer
View on ClinicalTrials.gov · NCT07061964Parallel Phase III Randomized Trials for High-Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation
View on ClinicalTrials.gov · NCT04513717Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate-Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation
View on ClinicalTrials.gov · NCT05050084Memantine +/– Raloxifene for Cognitive Preservation After Radiation Therapy to the Brain
View on ClinicalTrials.gov · NCT07470606Vertebral Bone Marrow in Lung Cancer Attention Trial (VMAT)
View on ClinicalTrials.gov · NCT05248256